Nobuhiro Shibata

15PUBLICATIONS
40CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersPharmacogenomicsHaematological tumoursNutritional epidemiology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|May 13, 2026
Randomised, multicentre phase II study of bevacizumab and paclitaxel induction followed by atezolizumab and nab-paclitaxel in patients with PD-L1-positive metastatic triple-negative breast cancer: protocol for the INDUCE trial (JBCRG-M10).

|Apr 05, 2026
Efficacy of olanzapine for prophylaxis of delayed chemotherapy-induced nausea and vomiting in patients with breast cancer receiving dose-dense AC with a steroid-sparing regimen: a single-center pilot study.

Manami Tada, Yuichiro Kikawa, Nobuhiro Shibata

|Mar 15, 2026
Impact of peritoneal metastasis on overall survival in patients with advanced endometrial cancer receiving lenvatinib plus pembrolizumab.

Shogen Boku, Masato Kita, Tatsuki Ikoma

|Nov 22, 2025
The safety and effectiveness of pegfilgrastim to reduce cancer chemotherapy-induced febrile neutropenia in real-world practice in Japan: a post-marketing surveillance study.

Nobuhiro Shibata, Hiroshi Kuwazawa, Tomoharu Yasukawa

|Jul 10, 2025
Relationship between the effectiveness of pembrolizumab monotherapy and ABO blood type in recurrent and metastatic squamous cell carcinoma of the head and neck.

Shogen Boku, Tatsuki Ikoma, Tomoyo Yasuda

|Jun 23, 2025
Correction: Real‑world evidence from Japan regarding survival outcomes and treatment sequence in patients receiving CDK4/6 inhibitor plus endocrine therapy as first‑ or second‑line treatment for hormone receptor-positive, HER2‑negative advanced or metastatic breast cancer.

Tetsuhiro Yoshinami, Yuko Takano, Yukinori Ozaki

Pageof 3

Frequent Collaborators

5 joint publications

Shogen Boku

4 joint publications

Tatsuki Ikoma

3 joint publications

Norikazu Masuda

3 joint publications

Toshihiko Matsumoto